Kim, Kunhwa
Jabbour, Elias
Short, Nicholas J.
Kebriaei, Partow
Kantarjian, Hagop
Ravandi, Farhad
Article History
Accepted: 30 April 2021
First Online: 14 June 2021
Declarations
:
: Kunhwa Kim declares that she has no conflict of interest. Elias Jabbour has received research funding and compensation for service as a consultant from Amgen, AbbVie, Adaptive Biotechnologies, Bristol-Myers Squibb, Genentech, Pfizer, Takeda, and Ascentage Pharma. Nicholas J. Short has received research funding from Takeda Oncology and Astellas; has received compensation for service as a consultant from Takeda Oncology and AstraZeneca; and has received honoraria from Amgen. Partow Kebriaei has received research funding from Amgen and Ziopharm; has received compensation for service as a consultant from Jazz Pharmaceuticals; and has participated on advisory boards for Pfizer, Kite Pharma, and Novartis. Hagop Kantarjian has received research funding from AbbVie, Amgen, Ascentage Pharma, Bristol-Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, Novartis, Pfizer, and Sanofi; has received honoraria from AbbVie, Amgen, Daiichi Sankyo, Novartis, Pfizer, Adaptive Biotechnologies, Aptitude Health, Bio Ascend, Delta-Fly Pharma, Janssen Global, Oxford Biomedical Technologies, and Takeda; and has served on an advisory board for Actinium Pharmaceuticals. Farhad Ravandi has received research funding from Bristol-Myers Squibb, and has received compensation for service as a consultant from Bristol-Myers Squibb, Novartis, Pfizer, and Takeda.
: This article does not contain any studies with human or animal subjects performed by any of the authors.